Thyrocare Technologies Ltd

Revenue from operations rose 24.34% year-on-year (YoY) to Rs 240.02 crore, driven by sustained momentum in the pathology segment. Profit before tax (PBT) increased 35.28% YoY to Rs 68.29 crore in the quarter ended 30th June 2026. EBITDA grew 34% YoY to Rs 77.27 crore, while the EBITDA margin improved to 32.2% in Q1 FY27 from 29.9% in Q1 FY26, reflecting improved operating efficiency. The pathology segment registered a 26% YoY growth in revenue to Rs 225.6 crore. Within the segment, franchise revenue increased 27% to Rs 142.8 crore, while partnership revenue rose 26% compared with the year-ago period. Operationally, the company processed 55.2 million diagnostic tests during the quarter, up 28% YoY. Revenue per test stood at Rs 39.8, down 2% from a year earlier, while revenue per patient increased 7% YoY to Rs 404. The company said it expanded into specialty diagnostics, marking the next phase of its growth journey and the next frontier of its diagnostics business. It began this journey with allergy and genomics testing and has since progressively expanded its specialty test portfolio, with a focus on building clinical trust through scientific rigor, uncompromising quality, and industry-leading turnaround times. Rahul Guha, MD & CEO, Thyrocare Technologies, said, 'Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India.' Thyrocare Technologies is the advanced fully automated laboratory chain with a strong presence PAN India. The company focuses on providing quality and affordable diagnostic services to laboratories and hospitals. It has a quarterly active franchise count of approximately 11,700 and processed 55.2 million diagnostic and screening investigations in Q1FY27.Powered by Capital Market - Live

Net profit of Thyrocare Technologies rose 34.06% to Rs 52.19 crore in the quarter ended June 2026 as against Rs 38.93 crore during the previous quarter ended June 2025. Sales rose 24.34% to Rs 240.02 crore in the quarter ended June 2026 as against Rs 193.03 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales240.02193.03 24 OPM %32.1929.93 - PBDT80.7861.89 31 PBT68.2950.48 35 NP52.1938.93 34 Powered by Capital Market - Live

Thyrocare Technologies will hold a meeting of the Board of Directors of the Company on 23 July 2026.

Thyrocare Technologies announced that the Annual General Meeting(AGM) of the company will be held on 30 June 2026.

Profit before tax (PBT) climbed 36.53% to Rs 64.43 crore in the quarter ended 31st March 2026. During the quarter, EBITDA increased 31% YoY to Rs 75.09 crore in Q4 FY26 with EBITDA margin improved 34% in Q4 FY26 over Q4 FY25. During the quarter, the company processed 59 million test, up 29% YoY. Revenue from pathology business jumped 21% YoY. The company reduced the complaints to 3.1 per million (down 34% YoY) with average turnaround time (ATAT) at 3.43 hours from sample receipt. The company said that it has epanded test portfolio with advanced allergy testing (over 250 SKUs on the Phadia platform) and entered genomics with a state-of-the-art lab and launch of Non-invasive Pre-Natal Testing (NIPT), alongside a phased expansion of its test menu to deepen clinical offerings in precision diagnostics. On a full year basis, the company's consolidated net profit climbed 78.18% to Rs 163.05 crore on 20.61% rise in revenue from operations to Rs 829.04 crore in FY26 over FY25. Rahul Guha, MD & CEO, Thyrocare Technologies, said, ''Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India.' Meanwhile, the company's board recommended a final dividend of Rs 7.00 per equity share for the financial year 2025' 26. In addition, the company's board approved the re-appointment of Rahul Franklin Guha as chairman, managing director & chief executive officer for a further period of five years commencing from May 4, 2027 to May 3, 2032 (both days inclusive). Further, the company's board has approved an investment of up to Rs 5.5 crore in one or more tranches through subscription to the equity shares of Think Health Diagnostics. Thyrocare Technologies is the advanced fully automated laboratory chain with a strong presence PAN India. The company focuses on providing quality and affordable diagnostic services to laboratories and hospitals. It has a quarterly active franchise count of around 10,800 and processed 59.0 million diagnostic and screening investigations in Q4FY26. Powered by Capital Market - Live

Thyrocare Technologies announced that the Board of Directors of the Company at its meeting held on 7 May 2026, inter alia, have recommended the final dividend of Rs 7 per equity Share (i.e. 70%) , subject to the approval of the shareholders.

Net profit of Thyrocare Technologies rose 117.14% to Rs 47.12 crore in the quarter ended March 2026 as against Rs 21.70 crore during the previous quarter ended March 2025. Sales rose 19.66% to Rs 223.95 crore in the quarter ended March 2026 as against Rs 187.16 crore during the previous quarter ended March 2025. For the full year,net profit rose 78.18% to Rs 163.05 crore in the year ended March 2026 as against Rs 91.51 crore during the previous year ended March 2025. Sales rose 20.61% to Rs 829.04 crore in the year ended March 2026 as against Rs 687.35 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales223.95187.16 20 829.04687.35 21 OPM %33.5330.49 -31.6127.49 - PBDT78.4660.96 29 277.62200.70 38 PBT64.4347.19 37 219.04145.44 51 NP47.1221.70 117 163.0591.51 78 Powered by Capital Market - Live

Thyrocare Technologies will hold a meeting of the Board of Directors of the Company on 7 May 2026.

Thyrocare Technologies has allotted 3,624 equity shares under ESOS on 02 March 2026. With this allotment, the paid up equity share capital has increased 15,91,65,315 equity shares of Rs 10 each. Powered by Capital Market - Live

Thyrocare Technologies will hold a meeting of the Board of Directors of the Company on 28 January 2026.Powered by Capital Market - Live